Naveen Pemmaraju

Naveen Pemmaraju: Bromodomain and PLX51107 with Azacitidine in Patients with R/R Myeloid Malignancies

Naveen Pemmaraju, Professor and Director of BPDCN Program at the Department of Leukemia at the University of Texas MD Anderson Cancer Center, shared a paper he and his colleagues authored on X:

“Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies.”

Authors: Jayastu Senapati et al.

Naveen pemmaraju

cancer Courtney D. DiNardo Darla Miller Elias Jabbour Farhad Ravandi Gautam Borthakur Ghayas C. Issa Guillermo Garcia-Manero Jan Burger Jayastu Senapati Joseph D. Khoury Kapil N. Bhalla Koji Sasaki Lucia Masarova Marina Konopleva Nathaniel R. Wilson Naval Daver Naveen Pemmaraju Nicholas J. Short Nitin Jain OncoDaily Oncology Sherry Pierce Tapan Kadia Warren C. Fiskus Wei Qiao Yesid Alvarado